Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

被引：0

作者：

Santoro, Armando ^{[1
,2
]}

Johnson, Nathalie A. ^{[3
]}

Savage, Kerry J. ^{[4
]}

Avigdor, Abraham ^{[5
]}

Bazargan, Ali ^{[6
,7
]}

Borchmann, Peter ^{[8
]}

Gasiorowski, Robin ^{[9
]}

Gregory, Gareth P. ^{[10
]}

Herishanu, Yair ^{[11
]}

Madan, Sumit ^{[12
]}

Minuk, Leonard ^{[13
,14
]}

Musuraca, Gerardo ^{[15
]}

West, Rachel Marceau ^{[16
]}

Pillai, Pallavi ^{[16
]}

Marinello, Patricia ^{[16
]}

Zinzani, Pier Luigi ^{[17
,18
]}

机构：

[1] Humanitas Univ, Pieve Emanuele, Milan, Italy

[2] IRCCS Humanitas Res Hosp Humanitas Canc Ctr Rozza, Milan, Italy

[3] Jewish Gen Hosp, Montreal, PQ, Canada

[4] BC Canc, Div Med Oncol, Vancouver, BC, Canada

[5] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[6] Univ Melbourne, Melbourne, Vic, Australia

[7] St Vincents Hosp, Fitzroy, Vic, Australia

[8] Univ Hosp Cologne, Cologne, Germany

[9] Univ Sydney, Concord Hosp, Concord, NSW, Australia

[10] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia

[11] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[12] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[13] CancerCare Manitoba, Winnipeg, MB, Canada

[14] Univ Manitoba, Winnipeg, MB, Canada

[15] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, Italy

[16] Merck & Co Inc, Rahway, NJ USA

[17] Univ Bologna Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy

[18] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth P.
Herrera, Alex F.
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Nahar, Akash
Timmerman, John
BLOOD, 2022, 140 : 6540 - 6542
[2] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth
Herrera, Alex Francisco
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Marinello, Patricia
Timmerman, John
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Tsoran-Rosenthal, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Nahar, Akash
Herrera, Alex F.
BLOOD, 2022, 140
[4] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth
Keane, Colm
Inna, Tzoran
Vucinic, Vladan
Zinzani, Pier Luigi
Zhang, Hong
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Zhu, Jun
Song, Yuqin
Guo, Ye
Zhou, Keshu
Li, Wenyu
Yang, Yu
Cai, Qingqing
Wang, Zhao
Yang, Haiyan
BLOOD, 2023, 142
[6] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
[7] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Witzig, Thomas E.
Maddocks, Kami J.
De Vos, Sven
Lyons, Roger M.
Edenfield, William Jeffery
Sharman, Jeff Porter
Vose, Julie
Yimer, Habte Aragaw
Wei, Helen
Chan, Edward M.
Patel, Priti
Di Simone, Christopher
Gandhi, Mitul
Vaughn, Jennifer
Kolibaba, Kathryn
Cheson, Bruce D.
Samaniego, Felipe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
de Vos, S
Fernando, D
Schenkein, DP
Rosen, PJ
BLOOD, 2005, 106 (11) : 267B - 267B
[9] Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.
Cobb, Patrick Wayne
Zhou, Heng
Nahar, Akash
Marinello, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →